Last reviewed · How we verify
Intravitreal Aflibercept Injection 2mg
Intravitreal Aflibercept Injection 2mg, marketed by Tennessee Retina, holds a significant position in the ophthalmic therapeutic market. The key composition patent, set to expire in 2028, provides a strong competitive advantage by protecting the drug's unique formulation. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Intravitreal Aflibercept Injection 2mg |
|---|---|
| Also known as | Aflibercept; EYLEA®; VEGF Trap-Eye, IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye |
| Sponsor | Tennessee Retina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
- Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
- Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery (PHASE4)
- The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy (PHASE2)
- Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment (NA)
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (PHASE2)
- Aflibercept and Bevacizumab for Diabetic Maculopathies (PHASE4)
- A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal Aflibercept Injection 2mg CI brief — competitive landscape report
- Intravitreal Aflibercept Injection 2mg updates RSS · CI watch RSS
- Tennessee Retina portfolio CI